Allspring Global Investments Holdings LLC raised its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 15.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 133,604 shares of the company's stock after acquiring an additional 18,274 shares during the period. Allspring Global Investments Holdings LLC's holdings in Sanofi were worth $7,260,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Lee Danner & Bass Inc. bought a new stake in shares of Sanofi in the fourth quarter valued at approximately $31,000. Bessemer Group Inc. boosted its stake in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after buying an additional 242 shares during the period. Golden State Wealth Management LLC boosted its stake in shares of Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after buying an additional 545 shares during the period. UMB Bank n.a. boosted its stake in shares of Sanofi by 30.7% in the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after buying an additional 264 shares during the period. Finally, AdvisorNet Financial Inc boosted its stake in shares of Sanofi by 16.4% in the first quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company's stock valued at $89,000 after buying an additional 227 shares during the period. Institutional investors own 14.04% of the company's stock.
Analyst Ratings Changes
SNY has been the subject of several recent analyst reports. Barclays restated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. The Goldman Sachs Group initiated coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price for the company. Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. BNP Paribas initiated coverage on Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price for the company. Finally, Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Three analysts have rated the stock with a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $61.50.
Get Our Latest Stock Report on SNY
Sanofi Price Performance
Shares of NASDAQ:SNY traded up $0.02 during trading on Monday, hitting $48.32. 2,305,572 shares of the company were exchanged, compared to its average volume of 2,338,380. The business's 50 day moving average is $50.52 and its 200-day moving average is $52.12. The company has a market capitalization of $118.50 billion, a P/E ratio of 17.26, a price-to-earnings-growth ratio of 1.05 and a beta of 0.48. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. The company had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The company's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.78 earnings per share. Equities analysts forecast that Sanofi will post 4.36 earnings per share for the current year.
Sanofi Increases Dividend
The business also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were issued a $2.0369 dividend. This represents a yield of 3.1%. This is an increase from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend was Friday, May 9th. Sanofi's dividend payout ratio is presently 57.14%.
Sanofi Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Recommended Stories

Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.